Short Interest in Yarrow Bioscience (NASDAQ:YARW) Drops By 93.2%

Yarrow Bioscience (NASDAQ:YARW) saw a large drop in short interest in July. As of July 31st, there was short interest totaling 12,582 shares, a drop of 93.2% from the July 15th total of 183,974 shares. Currently, 1.9% of the company’s stock are short sold. Based on an average trading volume of 38,657 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. TD Cowen assumed coverage on shares of Yarrow Bioscience in a research note on Tuesday, July 28th. They set a “buy” rating on the stock. BTIG Research initiated coverage on shares of Yarrow Bioscience in a research note on Monday, August 3rd. They set a “buy” rating and a $58.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $58.00.

Yarrow Bioscience Trading Up 2.3%

Yarrow Bioscience stock traded up $0.97 during mid-day trading on Tuesday, hitting $42.94. The company had a trading volume of 5,423 shares, compared to its average volume of 11,468. Yarrow Bioscience has a 12 month low of $14.02 and a 12 month high of $46.95. The company has a market capitalization of $28.77 million, a price-to-earnings ratio of -2.26 and a beta of 1.95.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.